Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Immunotherapy of cancer using genetically engineered GD2-specific T cells

Immunotherapy of cancer using genetically engineered GD2-specific T cells

US Patent 9493740 · Granted Nov 15, 2016

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Chimeric antigen receptors with MYD88 and CD40 costimulatory domains2025
Methods and compositions for chimeric antigen receptor targeting cancer cells2025
Highly modular biepitopic and bispecific CAR-T cells for cancer immunotherapy2025
Reprogramming CD4 t cells into cytotoxic CD8 cells by forced expression of CD8ab2025
Constitutively active cytokine receptors for cell therapy2024
Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing 2024
CSGP4—specific chimeric antigen receptor for cancer2023
Car T-cells recognizing cancer-specific IL 13Ra22023
Cancer gene therapy targeting CD472023
Antibody based gene therapy with tissue-directed expression2023
Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted an2023
Platform for enhanced targeted delivery2022